by 
Cancer metabolism based therapeutics target cancer cells in novel ways by inhibiting metabolic pathways essential for cancer cell growth and proliferation. Metabolic pathways altered in cancer cells include glucose, glutamine, fatty acid, and nucleotide metabolism which cancer cells rely on more than normal cells to support rapid cell division and growth. The availability of novel therapeutics targeting different metabolic vulnerabilities of cancer is proving effective in delaying disease progression and improving survival in certain cancers. Traditional therapies like chemotherapy, radiation, and targeted therapies often fail over time as cancers evolve resistance. Focusing on novel metabolic targets gives hope of more durable responses.
The global Cancer Metabolism Based Therapeutics Market is estimated to be valued at US$ 210.2 Bn in 2023 and is expected to exhibit a CAGR of 95% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. With rising cancer incidence worldwide particularly in developing nations due to aging populations and lifestyle changes, the cancer patient pool continues growing rapidly. This significant patient base seeking effective treatment options is driving demand for cancer metabolism based novel drugs and combination therapies.
Market key trends:
There is an increased clinical focus on studying cancer metabolism altering drug combinations. Recent clinical trials are evaluating combinations of existing cancer drugs like metformin, 2-deoxyglucose or investigational cancer metabolism drugs with immunotherapy, targeted therapy or chemotherapy. Researchers hope drug combinations targeting different cancer metabolic vulnerabilities concurrently may improve response rates over single agents. Secondly, novel biotech startups are actively pursuing development of first-in-class drugs inhibiting specific cancer metabolic enzymes or transporters involved in glucose, glutamine or fatty acid metabolism. Their entry into clinical trials will expand treatment options if successful. Lastly, interest in drug repurposing for new cancer indications based on metabolism is also on the rise. For example, existing diabetes drug metformin is under investigation for several cancer types based on its metabolic effects.
Porter’s Analysis
Threat of new entrants: Low, as cancer metabolism based therapeutics market requires large investments in R&D activities along with strong distribution network.
Bargaining power of buyers: Moderate, as buyers have presence of generic and biosimilar alternatives.
Bargaining power of suppliers: Low, as key raw material suppliers do not have significant influence on this market.
Threat of new substitutes: Moderate, as other targeted cancer therapies can be used as alternative for cancer metabolism based therapeutics.
Competitive rivalry: High, as major players focusing on new product launches and mergers & acquisitions to gain higher market share.
Key Takeaways
The global Cancer Metabolism Based Therapeutics market is expected to witness high growth. The market size for 2024 is US$ 210.2 Bn registering a CAGR of 95% during the forecast period.
Regional analysis: North America holds the major share of cancer metabolism based therapeutics market and is expected to continue dominating the market during the forecast period. Presence of established players and increasing healthcare expenditure are the major factors driving the regional market growth.
Key players: Key players operating in the Cancer Metabolism Based Therapeutics market are Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca. Celgene Corporation and Calithera Biosciences, Inc. are some of the leading players focusing on new product launches for metabolism inhibitors and glutaminase inhibitors.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
